Katrine B. Melhus - Concepedia

Author

Katrine B. Melhus

Norwegian Cancer Society

Also Known As

Katrine B Melhus, Katrine B. Melhus, Katrine Brustad Melhus, Katrine Melhus, Luciano Cascione

Publications

296

Citations

H-Index

Concepts

All Affiliations

Norwegian Cancer Society Oslo University Hospital Bayer (Norway)University of Oslo Nordic Nanovector (Norway)

About

Katrine B. Melhus is an author at Norwegian Cancer Society specializing in oncology, medicine, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	123
2	Immunology	3	3	123
3	Radiation Medicine	2	2	78
4	Engineering	1	1	22
5	Pathology	1	1	45

Katrine B. Melhus

Publications

289

Citations

H-Index

Page 1

	Year	Citations
Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate Jostein Dahle, Jørgen Borrebæk, Thora J. Jónasdóttir, Blood	2007	80
Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy Jostein Dahle, Jørgen Borrebæk, Katrine B. Melhus, Nuclear Medicine and Biology Radiation MedicineInitial EvaluationRadiation TherapyMedicineImmunology	2006	56
Preparation of TH <sup>227</sup> -Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability Roy H. Larsen, Jostein Dahle, Katrine B. Melhus, Cancer Biotherapy and Radiopharmaceuticals	2007	48
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Jostein Dahle, Ada H. V. Repetto‐Llamazares, Camilla Mollatt, PubMed ImmunologyPathologyImmunotherapyCd37 EpitopeTumor Immunology	2013	45
In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab Jostein Dahle, Cecilie Krogh, Katrine B. Melhus, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineEngineeringRadiation TherapyImmunotherapyRadionuclide Therapy	2009	22
Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An <i>In Vitro</i> Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the <i>α</i> -Emitter <sup>227</sup> Th Katrine B. Melhus, Roy H. Larsen, Trond Stokke, Cancer Biotherapy and Radiopharmaceuticals	2007	19
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines Gro Elise Rødland, Katrine B. Melhus, Roman Generalov, Frontiers in Oncology	2019	19

Page 1